Collateral efficacy in drug discovery: taking advantage of the good (allosteric) nature of 7TM receptors

Trends in Pharmacological Sciences

Volumn 28, Issue 8, 2007, Pages 407-415

  Kenakin, Terry ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ARRESTIN; BRIMONIDINE; CATECHOLAMINE; G PROTEIN COUPLED RECEPTOR; IMIDAZOLINE;

PRIORITY JOURNAL; REVIEW;

ALLOSTERIC REGULATION; DRUG DESIGN; HUMANS; KINETICS; LIGANDS; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, G-PROTEIN-COUPLED; TREATMENT OUTCOME;

EID: 34447624153     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.06.009     Document Type: Review

References (73)

1. Kenakin T. New concepts in drug discovery: collateral efficacy and permissive antagonism. Nat. Rev. Drug Discov. 4 (2005) 919-927
2. Stephenson R.P. A modification of receptor theory. 1956. Br. J. Pharmacol. 11 (1997) 379-393
3. Kenakin T. Agonist-receptor efficacy II: agonist-trafficking of receptor signals. Trends Pharmacol. Sci. 16 (1995) 232-238
4. Meller E., et al. Comparative effects of receptor inactivation, 17 β-estradiol and pertussis toxin on dopaminergic inhibition of prolactin secretion in vitro. J. Pharmacol. Exp. Ther. 263 (1992) 462-469
5. Spengler D., et al. Differential signal transduction by five splice variants of the PACAP receptor. Nature 365 (1993) 170-175
6. Lawler C.P., et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20 (1999) 612-627
7. 1 agonist containing a rigid β phenyldopamine pharmacophore. J. Med. Chem. 39 (1996) 549-555
8. Kenakin T. Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol. Sci. 24 (2003) 346-354
9. Urban J.D., et al. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 320 (2006) 1-13
10. 2A-adrenoceptor responses in HEL 92.1.7 cells. Br. J. Pharmacol. 132 (2001) 1477-1484
11. Watson C., et al. The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. Mol. Pharmacol. 58 (2000) 1230-1238
12. i protein interactions. Mol. Pharmacol. 67 (2005) 2016-2024
13. 5]enkephalin. J. Biol. Chem. 276 (2001) 37779-37786
14. 2+ current in mouse ventricular myocytes. Mol. Pharmacol. 56 (1999) 485-493
15. Kenakin T. Pharmacological proteus. Trends Pharmacol. Sci. 16 (1995) 256-258
16. Kenakin T. Protean agonists: keys to receptor active state?. Ann. N. Y. Acad. Sci. 812 (1997) 116-125
17. Terrillon S., and Bouvier M. Receptor activity-independent recruitment of β-arrestin reveals specific signaling modes. EMBO J. 23 (2004) 3950-3961
18. Lefkowitz R.J., and Shenoy S.K. Transduction of receptor signals by β-arrestins. Science 308 (2005) 512-517
19. Luttrell L.M. Composition and function of G protein-coupled receptor signalsomes controlling mitogen-activated protein kinase activity. J. Mol. Neurosci. 26 (2005) 253-263
20. Wei H., et al. Independent β-arrestin 2 and G-protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 10782-10787
21. Azzi M., et al. β-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G-protein-coupled receptors. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 11406-11411
22. Gesty-Palmer D., et al. Distinct β-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J. Biol. Chem. 281 (2006) 10856-10864
23. 2-adrenoceptor provide evidence for agonist-directed signaling. Mol. Pharmacol. 64 (2003) 1357-1369
24. Kohout T.A. Differential desensitization, receptor phosphorylation, β-arrestin recruitment, and ERK1/2 activation by two endogenous ligands for the CC chemokine receptor 7. J. Biol. Chem. 279 (2004) 23214-23222
25. Johnson E.A., et al. Agonist-selective mechanisms of μ-opioid receptor desensitization in human embryonic kidney 293 cells. Mol. Pharmacol. 70 (2006) 676-685
26. Groer C.E., et al. An opioid agonist that does not induce μ-opioid receptor-arrestin interactions or receptor internalization. Mol. Pharmacol. 71 (2007) 549-557
27. 2A receptors by agonists and antagonists. Brain Res. Bull. 56 (2001) 441-451
28. Roettger B.F., et al. Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol. Pharmacol. 51 (1997) 357-362
29. Sneddon W.B., et al. Activation-independent parathyroid hormone receptor internalization is regulated by NHERF1 (EPB50). J. Biol. Chem. 278 (2003) 43787-43796
30. Willins D.L., et al. Clozapine and other 5-hydroxytryptamine-2A receptor antagonists alter the subcellular distribution of 5-hydroxytryptamine-2A receptors in vitro and in vivo. Neuroscience 91 (1999) 599-606
31. 2A receptors during endocytosis. J. Biol. Chem. 276 (2001) 8269-8277
32. Amara A., et al. HIV coreceptor downregulation as antiviral principle: SDF-1α-dependent internalization of the chemokine receptor CXCR4 contributes to inhibition of HIV replication. J. Exp. Med. 186 (1997) 139-146
33. Feng Z., et al. Huamn β-defensin3- a novel antagonist of the HIV-1 coreceptor CXCR4. J. Immunol. 177 (2006) 782-786
34. Perry S.J., et al. Distinct conformations of the corticotrophin releasing factor type 1 receptor adopted following agonist and antagonist binding are differentially regulated. J. Biol. Chem. 280 (2005) 11560-11568
35. Pheng L.H., et al. Agonist- and antagonist-induced sequestration/internalization of neuropeptide YY1 receptors in HEK293 cells. Br. J. Pharmacol. 139 (2003) 695-704
36. Blanpain C., et al. Multiple active states and oligermization of CCR5 revealed by functional properties of monoclonal antibodies. Mol. Biol. Cell 13 (2002) 723-737
37. Pastori C., et al. Long-lasting CCR5 internalization by antibodies in a subset of long-term nonprogressors: a possible protective effect against disease progression. Blood 107 (2006) 4825-4833
38. 2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveal the pluridimensionality of efficacy. Mol. Pharmacol. 70 (2006) 1575-1584
39. Kukkonen J.P. Regulation of receptor-coupling to (multiple) G proteins. A challenge for basic research and drug discovery. Receptors Channels 10 (2004) 167-183
40. Hermans E. Biochemical and pharmacological control of the multiplicity of coupling at G-protein receptors. Pharmacol. Ther. 99 (2003) 25-44
41. Perez D.M., and Karnick S.S. Multiple signaling states of G-protein coupled receptors. Pharmacol. Rev. 57 (2005) 147-161
42. Hilser V.J., et al. The structural distribution of cooperative interactions in proteins: analysis of the native state ensemble. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 9903-9908
43. Woodward C. Is the slow-exchange core the protein folding core?. Trends Biochem. Sci. 18 (1993) 359-360
44. Frauenfelder H., et al. The energy landscapes and motions of proteins. Science 254 (1991) 1598-1603
45. Okada T., and Palczewski K. Crystal structure of rhodopsin: implications for vision and beyond. Curr. Opin. Struct. Biol. 11 (2001) 420-426
46. 2-adrenergic receptor: evidence for ligand specific conformational changes. J. Biol. Chem. 270 (1995) 28268-28275
47. 2-adrenergic receptor. J. Biol. Chem. 276 (2001) 24433-24436
48. Palanche T., et al. The neurokinin A receptor activates calcium and cAMP responses through distinct conformational states. J. Biol. Chem. 276 (2001) 34853-34861
49. 2 adrenoceptor: kinetic evidence for intermediate conformational states. J. Biol. Chem. 279 (2004) 686-691
50. Burgen A.S.V. Conformational changes and drug action. Fed. Proc. 40 (1966) 2723-2728
51. Kenakin T.P. Collateral efficacy as a pharmacological problem applied to new drug discovery. Expert. Opin. Drug Disc. 1 (2006) 635-652
52. Kenakin T. Efficacy at G protein coupled receptors. Annu. Rev. Pharmacol. Toxicol. 42 (2002) 349-379
53. Costa T., et al. Opioid receptors are coupled tightly to G proteins but loosely to adenylate cyclase in NG108-15 cell membranes. Mol. Pharmacol. 34 (1988) 744-754
54. Jakubik J., et al. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol. Pharmacol. 52 (1997) 172-179
55. Maeda K., et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J. Virol. 78 (2004) 8654-8662
56. Watson C., et al. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric non-competitive HIV entry-inhibitor. Mol. Pharmacol. 67 (2005) 1268-1282
57. Ehlert F.J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol. 33 (1988) 187-194
58. Black J.W., and Leff P. Operational models of pharmacological agonists. Proc. Roy. Soc. Lond. (Biol.) 220 (1983) 141-162
59. Kenakin T., et al. Determining the potency and molecular mechanism of action of insurmountable antagonists. J. Pharmacol. Exp. Ther. 319 (2006) 710-723
60. Watson C., et al. Relationships between aplaviroc binding to CCR5 and binding of Sch-C, Sch-D, TAK779 and UK-427,857. Society for Biomolecular Sciences Handbook (2006), Sage 169
61. Hunton D.L., et al. β-Arrestin 2-dependent angiotensin II type 1A receptor-mediated pathway of chemotaxis. Mol. Pharmacol. 67 (2006) 1229-1236
62. Defea K.A., et al. β-Arrestin-dependent endocytosis of proteinase-activated receptor 2 is required for intracellular targeting of activated ERK1/2. J. Cell Biol. 148 (2000) 1267-1281
63. 1a receptor stimulation. J. Biol. Chem. 277 (2002) 9429-9436
64. Sanchez-Sanchez N., et al. The multiple personalities of the chemokine receptor CCR7 in dendritic cells. J. Immunol. 176 (2006) 5153-5159
65. Vassart G., and Dumont J.E. The thyrotropin receptor and the regulation of thyrocyte function and growth. Endocr. Rev. 13 (1992) 596-611
66. Mazzocchi G., et al. Human pheochromocytomas express orexin receptor type 2 gene and display an in vitro secretory response to orexins A and B. J. Clin. Endocrinol. Metab. 86 (2001) 4818-4821
67. Mazzocchi G., et al. Orexin A stimulates cortisol secretion from human adrenocortical cells through activation of the adenylate cyclase-dependent signaling cascade. J. Clin. Endocrinol. Metab. 86 (2001) 778-782
68. Kenakin T.P. Efficacy at G protein coupled receptors. Nat. Rev. Drug Discov. 1 (2002) 103-109
69. MacKinnon A.C., et al. Bombesin and substance P analogues differentially regulate G-protein coupling to the bombesin receptor. Direct evidence for biased agonism. J. Biol. Chem. 276 (2001) 28083-28091
70. Duane E., et al. Morphine activates opioid receptors without causing their rapid internalization. J. Biol. Chem. 271 (1996) 19021-19024
71. Ryman-Rasmussen J.P., et al. Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists. Mol. Pharmacol. 68 (2005) 1039-1048
72. 5]-enkephalin-μ-opioid receptor complexes demonstrated by cAMP-dependent protein kinase phosphorylation. J. Neurochem. 71 (1998) 231-239
73. Audet N., et al. Internalization and Src activity regulate the time course of ERK activation by δ opioid receptor ligands. J. Biol. Chem. 280 (2005) 7808-7816